The rationale for neoadjuvant targeted therapy (BRAF and MEK inhibitors) in melanoma centers on achieving rapid reduction in tumor burden, improving resectability, and potentially enhancing long-term outcomes. This evidence concerns the gene MAP2K7 and melanoma.